People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

The manufacturer of semaglutide, Novo Nordisk, plans to seek U.S. Food and Drug Administration (FDA) approval for the drug to ...

The federal judge overseeing the case of the Maryland resident who was mistakenly sent to a prison in El Salvador granted the Trump administration a week-long pause in detailing what steps ...

The FDA may begin enforcement actions against pharmacies compounding unauthorized semaglutide after May 22, 2025. Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous ...